Biopharma Daily Stock Updates - 09/21/21

$XBI $130.25 +1.16%

---

Pipeline Updates

$BLUE +0.1% bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions. source

$INCY +0.2% Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD). source

$NKTR +8.5% Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study. source

$MIRM +0.5% Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan. source

$CUE +5.7% Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101. source

$ATAI +2.6% DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder. source

$DRMA +2.7% Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting. source

$PCRX +3.2% Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries. source

$CLSD +2.5% Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients. source

$STOK +5.7% Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome. source

$ORIC -2.2% ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor. source

$HCM 0% HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China. source

$SLDB +20.3% Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001. source

$PTGX +18.2% On 9/17 Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program. source

$CRVS +38.3% Corvus shares surged on Friday after AZN/IPHA reported favorable results of CD73 monoclonal antibody earlier in week. source

Finance & Business Updates

$LPTX +23.1% Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants. source

$RVVTF +3.2% Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF. source

$BDTX -0.4% Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform. source

$VECT -0.5% VectivBio Announces Closing of Comet Therapeutics Acquisition. source

---

Posted by FS